Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517582 · ClinicalTrials.gov registry record · Phase 1
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00517582 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 13 participants.
The verdict
NCT00517582, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. This study will evaluate the effectiveness of the drug HOE-140 at decreasing symptoms of angioedema in people taking ACE inhibitors who develop the condition.
Interventions
- OTHER Placebo
- DRUG HOE-140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517582
The ClinicalTrials.gov registry entry for NCT00517582 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00517582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517582 about?
NCT00517582 is a clinical study titled "Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema". Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other bod...
What is the current status of trial NCT00517582?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2007-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00517582?
The interventions under investigation include: Placebo (OTHER), HOE-140 (DRUG).
Who is sponsoring clinical trial NCT00517582?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.